絞り込み

17410

広告

「"Drelichman G "[Author]」の検索結果

23件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

[Phaeohyphomycosis by Exserohilum rostratum in a pediatric patient with acute lymphoblastic leukemia after bone marrow transplantation].

The Road to Biosimilars in Rare Diseases - Ongoing Lessons from Gaucher Disease.

Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.

Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency.

Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.

Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study.

Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy.

Evaluation of Bone Mineral Density in Patients with Type 1 Gaucher Disease in Argentina.

Skeletal Involvement in Gaucher Disease: An Observational Multicenter Study of Prognostic Factors in the Argentine Gaucher Disease Patients.

Prodromal Clinical Markers of Parkinson disease in Gaucher Disease Individuals.

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.

Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.

[Gaucher disease in Latin America. A report from the Gaucher Disease International Registry and the Latin American Group for Gaucher Disease].

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

[Not available].

[Not available].

[Not available].

Management of transfusional iron overload in Latin America: current outlook and expert panel recommendations.

Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

  1. 1
  2. 2
Sort by
※並べ替えは表示に時間がかかります